ASH 2025 Signals Shift Toward Personalized, Time-Limited Therapy in Chronic Lymphocytic Leukemia

Lauren M. Granat, DO, MS Cleveland Clinic

Key Points

• Data presented at the 2025 ASH Annual Meeting (ASH 2025) support a continued shift toward personalized, targeted, and time-limited treatment strategies in chronic lymphocytic leukemia (CLL).

• Fixed-duration regimens demonstrated outcomes comparable with continuous Bruton tyrosine kinase (BTK) inhibition in frontline disease.

• Noncovalent BTK inhibitors, particularly pirtobrutinib, are emerging as important options earlier in the treatment sequence.

• Minimal residual disease (MRD) assessment continues to evolve as a prognostic tool, though its role in guiding treatment duration remains investigational.

The treatment landscape for CLL is evolving rapidly, and data presented at ASH 2025 underscore a clear trend toward increasingly personalized, targeted, and time-limited therapeutic strategies. Across multiple late-breaking oral presentations and expert-driven discussions, investigators highlighted advances that balance efficacy, durability, toxicity, and patient-centered goals, moving the field further away from a one-size-fits-all approach.

A central theme was the maturation of fixed-duration therapy as a viable, evidence-based alternative to continuous BTK inhibition in the frontline setting. Results from the phase 3 CLL17 trial demonstrated that time-limited regimens, including venetoclax plus obinutuzumab and venetoclax plus ibrutinib, were noninferior to continuous ibrutinib with respect to investigator-assessed progression-free survival (PFS) in previously untreated patients with CLL. Although longer follow-up is needed, these findings validate time-limited strategies across a broad patient population and support their broader adoption in clinical practice.

Continuous BTK inhibition, however, remains an important option, particularly for patients with very high-risk disease biology or those prioritizing maximal PFS. Long-term follow-up from studies such as RESONATE, showing a median PFS approaching 9 years among patients able to remain on therapy, continues to reinforce the durability of this approach.

Highlighting the Growing Role of BTK Inhibitors 

Another major focus of ASH 2025 was the expanding role of noncovalent BTK inhibitors, particularly pirtobrutinib (Jaypirca). Two large phase 3 studies were highlighted. In BRUIN CLL-313, pirtobrutinib significantly improved PFS compared with bendamustine plus rituximab in treatment-naive patients with CLL/small lymphocytic lymphoma. In addition, the first head-to-head phase 3 comparison with ibrutinib demonstrated noninferiority in overall response rate, with favorable trends across both treatment-naive and relapsed/refractory subgroups. These data support pirtobrutinib’s potential role earlier in the treatment sequence, challenging the historical dominance of covalent BTK inhibitors.

Additional presentations explored pirtobrutinib in combination strategies, including fixed-duration regimens with venetoclax and obinutuzumab, translational studies examining immune modulation, and exploratory analyses in Richter transformation. Collectively, these findings suggest that noncovalent BTK inhibition may continue to reshape treatment paradigms across disease settings.

Fixed-duration triplet targeted therapy—combining a BTK inhibitor, venetoclax, and an anti-CD20 antibody—also generated significant interest. Data presented showed that regimens such as pirtobrutinib plus venetoclax and obinutuzumab can induce high rates of undetectable MRD in frontline patients, supporting a chemo-free approach aimed at deep remissions. However, investigators emphasized caution: Triplet regimens are associated with increased toxicity and should be reserved for fit, younger patients with high-risk disease. For favorable-risk patients, including those with mutated IGHV, doublet regimens already deliver excellent outcomes without the added risk.

Exploring MRD, Relapsed Disease, and Treatment Sequencing

MRD emerged as another defining theme of the meeting. Adaptive Biotechnologies highlighted nearly 90 abstracts integrating MRD assessment using clonoSEQ next-generation sequencing, including CLL cohorts achieving very deep responses down to 10⁻⁶. Multiple interventional studies explored MRD-guided treatment decisions, marking an important step toward personalized therapy duration. Still, experts stressed that while MRD is strongly prognostic—particularly following venetoclax-based therapy—it should not guide treatment duration outside of clinical trials, as no evidence shows that extending therapy based solely on MRD positivity improves outcomes.

In the relapsed and refractory setting, clear definitions remain critical. True “double-refractory” disease—progression on both covalent BTK and BCL2 inhibitors—represents a particularly high-risk population. For these patients, pirtobrutinib and chimeric antigen receptor T-cell (CAR-T) therapy (lisocabtagene maraleucel) have emerged as key options. Treatment sequencing often favors pirtobrutinib first, especially in older patients, with CAR-T reserved for younger, fit individuals. Notably, BTK inhibitors may also serve as effective bridges to CAR-T by improving immune function prior to cellular therapy.

Taken together, data from ASH 2025 reinforce a rapidly evolving CLL treatment paradigm—one that prioritizes precision, flexibility, and patient-centered care, while continuing to expand the role of targeted, time-limited strategies across the disease continuum.